Nordisk – Page 3 – Talk Bio

Actionable Insights Powered by AI

Novo Nordisk Projects Slower Growth for 2025, Targets CagriSema Approval in 2026

6 months ago talkbio0Tagged 2025, CagriSema, Drug Industry, Growth, Nordisk, Obesity, regulatory approval, Sales - occupational activity, Wegovy

Novo Nordisk, 2025 outlook, CagriSema, obesity treatment, pharmaceutical industry, Wegovy, sales growth, regulatory approval

Novo Nordisk Projects Slower Growth for 2025 Despite Wegovy’s Strong Q4 Performance

6 months ago talkbio0Tagged Drug Industry, Growth, Nordisk, Obesity, Sales - occupational activity, Wegovy

Novo Nordisk, Wegovy, obesity drugs, sales growth, 2025 outlook, pharmaceutical industry

Omega Therapeutics Faces Bankruptcy and Layoffs Despite Recent Novo Nordisk Obesity Deal

6 months ago talkbio0Tagged Bankruptcy, deal, Epigenomics, financial struggles, Flagship, Nordisk, Obesity, Pioneering

Omega Therapeutics, bankruptcy, layoffs, Novo Nordisk, obesity deal, Flagship Pioneering, epigenomics, financial struggles

Novo Nordisk’s Obesity Drug Breakthrough: 22% Weight Loss at Week 36 Boosts Stock by 11%

6 months ago talkbio0Tagged 22%, amycretin, Drug Industry, next-gen, Nordisk, Obesity, semaglutide, Stock Surge, Weight Loss

Novo Nordisk, Obesity drug, 22% weight loss, Stock surge, Next-gen obesity treatment, Amycretin, Semaglutide, Pharmaceutical industry

High-Dose Wegovy Demonstrates Enhanced Weight Loss in Phase III Trial

6 months ago talkbio0Tagged Nordisk, Novo Nordisk, Obesity, Phase 3 Clinical Trials, semaglutide, Step (specific stage), Up, Wegovy

Wegovy, semaglutide, obesity treatment, weight loss, Novo Nordisk, Phase III trial, STEP UP trial

Novo Nordisk’s High-Dose Wegovy Demonstrates Superior Weight Loss of 20.7% in Phase IIIb Trial

6 months ago talkbio0Tagged Nordisk, Obesity, semaglutide, Step (specific stage), Trial Phase 3B, Up, Wegovy

Novo Nordisk, Wegovy, semaglutide, obesity treatment, weight loss, Phase IIIb trial, STEP UP trial

Novo Nordisk and Lilly Lead Clarivate’s 2025 ‘Drugs to Watch’ List with Breakthrough Therapies

7 months ago talkbio0Tagged blockbuster drugs, Clarivate, Drug Industry, Eli, Eli Lilly, gene therapy, Neoplasms, Nordisk, Obesity

Clarivate, Drugs to Watch 2025, Novo Nordisk, Eli Lilly, Obesity treatments, Gene therapy, Oncology, Blockbuster drugs, Pharmaceutical industry

Novo Nordisk and Valo Health Expand AI-Driven Collaboration to Develop Novel Treatments for Obesity, Type 2 Diabetes, and Cardiovascular Disease

7 months ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, biotech, Cardiovascular Diseases, Computational Technique, Diabetes, Drug Development, Nordisk, Obesity, Valo Health

Novo Nordisk, Valo Health, AI, Obesity, Type 2 Diabetes, Cardiovascular Disease, Drug Development, Computational Biotech

Novo Nordisk and Variant Bio Collaborate on Metabolic Disease Research, Focusing on Diverse Populations

7 months ago talkbio0Tagged benefit-sharing program, Bio, Diversity, Genetic Research, geographic population, Metabolic Diseases, Nordisk, Variant, VB-Inference platform

Novo Nordisk, Variant Bio, Metabolic disease, Genetic research, Diverse populations, VB-Inference platform, Benefit-sharing program

Novo Nordisk Seeks FDA Restriction on Victoza Compounding Amid Ongoing GLP-1 Supply Issues

7 months ago talkbio0Tagged Glucagon-Like Peptide 1, liraglutide, Nordisk, pharmaceutical regulation, United States Food and Drug Administration, Victoza

Novo Nordisk, FDA, Victoza, liraglutide, compounding, GLP-1, supply issues, pharmaceutical regulation